Siemens' Biograph Horizon PET/CT
Erlangen, Germany, October 13, 2016 -- At the 2016 Annual Meeting of the European Association of Nuclear Medicine (EANM), Oct. 15-19 in Barcelona, Spain, Siemens Healthineers highlights technical innovations that support standardization of patient care with the added potential to influence care pathways. This year, Siemens Healthineers debuts an expanded version of its xSPECT Quant™1 technology to enable quantification of three additional isotopes using its established Symbia Intevo™1 system – which represents the next step in the evolution of single-photon emission computed tomography/computed tomography (SPECT/CT). Additionally, Siemens Healthineers migrates its revolutionary FlowMotion™ continuous bed motion technology to the company's established Biograph Horizon™1 positron emission tomography/CT (PET/CT) system, which offers premium performance at an attractive total cost of ownership. With these two innovations, Siemens Healthineers helps healthcare providers improve care delivery and set new standards with molecular imaging.
Expanded capabilities for xSPECT Quant
Debuting at EANM 2016 is an expanded version of xSPECT Quant, an established SPECT quantification technology that enables users of the company's Symbia Intevo SPECT/CT system to perform automated, accurate and reproducible quantification of not just Technetium-99m – the most common isotope in SPECT imaging – but also, for the first time, Iodine-123, Lutetium-177, and Indium-111. This extends the use of advanced SPECT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, neuroblastoma, and metastatic prostate cancer.
xSPECT Quant is the first and only technology to use a 3% National Institute of Standards and Technology (NIST) traceable precision source,2 enabling standardization of standard uptake values (SUVs) for reliable disease detection and therapy response using different cameras or dose calibrators or at different treatment facilities. And the technology offers clinicians higher reproducibility than traditional post-reconstruction scaling methods of quantification. The absolute quantification capabilities of xSPECT Quant also can facilitate theranostics, an emerging approach employing radioactive isotopes that emit energies to not only image but also treat the patient's disease.
In addition to the expanded xSPECT Quant technology, Siemens Healthineers also debuts Broad Quantification™1, a more efficient manual quantification method for its Symbia Intevo system. Broad Quantification enables quantification of every available isotope and collimator combination in SPECT imaging.